Amgen "outperform," target price raised

22.01.09 - Leerink Swann & Co.

NEW YORK, January 22 (newratings.com) - Analysts at Leerink Swann & Co reiterate their "outperform" rating on Amgen Inc (AMGN). The target price has been raised from $75 to $76.50.